Pure Global AI
NCT06296836Not yet recruiting

Effect of Continuing Versus Holding Metformin During Hospitalizations.

Effect of Continuing Versus Holding Metformin During Hospitalizations to Internal Medicine on Glucose Control, Acidosis, Abdominal Symptoms, Length of Stay, and Mortality.
University of Illinois at ChicagoPhase 4ClinicalTrials.govdrug
Verified
Study focus
Disease/Condition
Diabetes Mellitus, Type 2
Drug/Device/Intervention
Metformin
Study type
Interventional
Intervention type
drug
Sponsor & location
Primary sponsor
University of Illinois at Chicago
Location
Chicago, United States of America
Timeline & enrollment
Phase
Phase 4
Start date
Apr 01, 2024
End date
Jun 30, 2026
Enrollment
300 participants
Primary outcome

Mean glucose levels

Summary

A randomized study of continuing versus holding metformin during hospitalizations to internal
 medicine services to determine the effects on glucose control, acidosis, abdominal symptoms,
 length of stay, and mortality.

ICD-10 classifications
Type 2 diabetes mellitusType 2 diabetes mellitus with unspecified complicationsType 2 diabetes mellitus with other specified complicationsType 2 diabetes mellitus without complicationsType 2 diabetes mellitus with multiple complications
Data source
Registry
ClinicalTrials.gov
Trial ID
NCT06296836
Type
Non-Device Trial
About this record

Access comprehensive clinical trial information for NCT06296836 through Pure Global AI's free database. This Phase 4 trial is sponsored by University of Illinois at Chicago and is currently Not yet recruiting. The study focuses on Diabetes Mellitus, Type 2. Target enrollment is 300 participants.

This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.